Stock Benefit Plans and Equity Transactions (Tables)

9 Months Ended

Sep. 30, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Total Stock Based Compensation

Stock-Based Compensation

Total stock-based compensation for the three and nine months ended September 30, 2020 is as follows (in thousands):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2020		2019		2020		2019
Cost of revenues	$	139	$	57	$	374	$	113
Research and development		379		227		1,066		543
Sales, general and administrative		4,026		3,319		11,247		6,910
Total	$	4,544	$	3,603	$	12,687	$	7,566

Summary of Common Stock Reserved for Future Issuance

As of September 30, 2020, the Company had reserved shares of its common stock for future issuance as follows (in thousands):

Stock options outstanding	4,141
Unvested restricted stock award	8,072
Employee stock purchase plan	394
Series A convertible preferred stock	29
Warrants outstanding	25,358
Authorized for future grant under the Distributor and    Development Services plans	6,783
Authorized for future grant under the Management    Objective Strategic Incentive Plan	345
Authorized for future grant under the Company equity    plans	5,190
Total	50,312

Summary of All Outstanding Warrants for Common Stock

A summary of all outstanding warrants for common stock is as follows:

	Number of Warrants		Strike Price		Expiration
2017 PIPE Warrants*		3,255,554	$	2.02	June 2022
2018 PIPE Warrants		11,527,147	$	3.50	May 2023
SafeOp Surgical Merger Warrants		2,185,099	$	3.50	May 2023
2018 Squadron Capital Warrants		845,000	$	3.15	May 2027
2019 Squadron Capital Warrants		4,838,710	$	2.17	May 2027
2020 Squadron Capital Warrants		1,075,820	$	4.88	May 2027
Executive Warrants		1,327,434	$	5.00	December 2022
Other*		302,812	$	3.85	Various through May 2023
Total		25,357,576

* Represents weighted average exercise price.